Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer
Supportive Care in Cancer · 2026-07 · 34 (7)
DOI: 10.1007/s00520-026-10904-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 26.06.2026. Verfasst von Kenneth Hu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Department of Otolaryngology-Head and Neck Surgery, New York University, New York, NY, USA. kenneth.hu@nyulangon…. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Low-Level Light Therapy, Radiation Injuries, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Funding for this study, including data collection, monitoring, statistical analysis and medical writing, was provided by MuReva Phototherapy Inc. (Brecksville,….
Abstract (Originalsprache)
Purpose
This study evaluated the safety and effectiveness of an intraoral light-emitting diode (LED)-based photobiomodulation (PBM) device to reduce the incidence and severity of oral mucositis (OM) from intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC).
Methods
This randomized, double-blind, sham-controlled trial enrolled patients with HNC undergoing high-dose IMRT over 6–8 weeks, with or without concurrent chemotherapy. Participants received daily 10-min PBM or sham treatments immediately before IMRT sessions. Assessments were conducted at baseline, daily and weekly during IMRT, and two weeks post-IMRT.
Results
Eighty-five participants (42 PBM; 43 sham) were enrolled across 12 US sites. No device-related adverse events were observed, and 99.5% of initiated sessions were completed. In the intent-to-treat population, severe OM (WHO Grade ≥ 3) incidence was significantly lower with PBM across six weeks of IMRT (36.8% vs 57.1%; p = 0.046) and at two weeks post-treatment (10.8% vs 36.4%; p = 0.042). In the per-protocol population, the PBM arm reported significantly greater taste preservation ( p = 0.034), lower increases in mouth/throat soreness ( p = 0.029) and throat pain ( p = 0.028) and needed fewer feeding tube placements ( p = 0.073) than the control arm.
Conclusion
Daily intraoral PBM therapy using an LED-based device was safe, well tolerated, and significantly reduced the incidence of severe OM and associated complications in HNC patients undergoing IMRT with or without concurrent chemotherapy. These findings align with guidelines recommending daily intraoral PBM therapy for preventing cancer therapy-related OM, a dose-limiting toxicity for which effective preventive interventions are needed. Trial Registration Clinical Trials.gov Registration Number NCT03972527. Registered on June 3, 2019. Concise Summary Daily intraoral PBM therapy using an LED-based device was safe, well tolerated, and significantly reduced the incidence of severe OM and associated complications in HNC patients undergoing IMRT with or without concurrent chemotherapy. These findings align with guidelines recommending daily intraoral PBM therapy for preventing cancer therapy-related OM, a dose-limiting toxicity for which effective preventive interventions are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology and Department of Otolaryngology-Head and Neck Surgery, New York University, New York, NY, USA. kenneth.hu@nyulangone.org.
- St. Elizabeth Healthcare, Edgewood, KY, USA.
- Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, USA.
- Christ Hospital, Cincinnati, OH, USA.
- University of Mississippi Medical Center, Jackson, MS, USA.
- University of Alabama at Birmingham, Birmingham, AL, USA.
ORCID-Profile: Kenneth Hu
Förderung
- Funding for this study, including data collection, monitoring, statistical analysis and medical writing, was provided by MuReva Phototherapy Inc. (Brecksville,…
Zitieren
APA
Hu, K., Shah, P., Nguyen, M. C., McCluskey, C., Kane, A., Ove, R., Willey, C. D., Katz, S., Marathe, O., Valentin, S., Frustino, J., Villa, A., Spencer, S., Holtzapfel, C., Treister, N., & Lalla, R. V. (2026). Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer. Supportive Care in Cancer, 34(7). https://doi.org/10.1007/s00520-026-10904-7
Vancouver
Hu K, Shah P, Nguyen MC, McCluskey C, Kane A, Ove R, et al. Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer. Supportive Care in Cancer. 2026;34(7). doi:10.1007/s00520-026-10904-7
BibTeX
@article{Hu2026,
author = {Hu, Kenneth and Shah, Pratish and Nguyen, M Connie and McCluskey, Cornelia and Kane, Anne and Ove, Roger and Willey, Christopher D and Katz, Sanford and Marathe, Omkar and Valentin, Sasha and Frustino, Jennifer and Villa, Alessandro and Spencer, Sharon and Holtzapfel, Catherine and Treister, Nathaniel and Lalla, Rajesh V},
title = {Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {7},
doi = {10.1007/s00520-026-10904-7}
}
EUVIMED